A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents

Maria Fasshauer,Gesine Schuermann,Norbert Gebert,Horst von Bernuth,Monika Bullinger,Sigune Goldacker,Renate Krueger,Petra Manzey,Stefanie Messner,Ellen D Renner,Henrike Ritterbusch,Uwe Schauer,Ilka Schulze,Volker Umlauf,Steffi Widmann,Ulrich Baumann
DOI: https://doi.org/10.1080/1750743X.2024.2367924
2024-07-29
Immunotherapy
Abstract:Aim: To assess a patient empowerment program (PEP) for children/adolescents with primary immunodeficiency (PID) on IgG replacement therapy regarding quality of life (QoL) in patients and proxy. Patients & methods: Health-related QoL was assessed using KIDSCREEN-27 and DISABKIDS-37 before and 6 months after PID-PEP kids in 19 children/adolescents and their parents. Results: The following three dimensions of the KIDSCREEN-27 significantly increased in children/adolescents after PID-PEP kids as compared with baseline: Psychological Well-Being, Parents & Autonomy and School Environment. Total DISABKIDS-37 index, as well as 5 of the 6 DISABKIDS-37 dimensions, significantly increased, in other words, Independence, Emotion, Social Inclusion, Social Exclusion and Physical. Evaluation of proxy instruments showed comparable results. Conclusion: PID-PEP kids significantly improved QoL in patients with PID.
What problem does this paper attempt to address?